The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?

Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.

The AerosolSense Bioaerosol Sampler, developed by Thermo Fisher, processes air in order to spot COVID-19 faster and with higher sensitivity than swab testing.

The winners of the XPRIZE will move on to collaborate with OpenCovidScreen, a non-profit founded by scientists and business leaders, to drive needed innovation through “Open Science.”